Skip to main content
$60.45 -1.70 (-2.74%) At close · Jul 24
Market Cap
$9.37B
Shares
154.99M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$62.15 Open$61.17 Day$60.75–63.48 52W$28.41–64.54 Avg vol 30d2.0M Short int14.6M · 9.4% float · 7.2d Short vol75% Last earningsAug 4, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 7

Up next

Next earnings call
Aug 4, 2026 Scheduled · in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 7, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 18.6 · elevated Equity put/call 0.79
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +38%
      above
      Price vs 50-day avg +12%
      above
      RSI (14) 60
      neutral
      MACD trend Negative
      52-week position 93%
      near high
      Momentum
      relative strength
      Very Strong
      1-month return +6%
      trailing
      6-month return +41%
      trailing
      YTD return +32%
      this year
      Relative strength +34%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $55 › 200d $45 — 50d above 200d
      Institutional flow Accumulating
      78 of 345 funds reported for Jun 30 · net +576.9K sh shares · +23 new
      Insider flow Distributing
      Net -$317.8K over 90 days · 100% sells
      Short interest Rising
      9.44% of float · ▲ +16.0% MoM · 7.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      345 holders — mid 3-yr range
      Squeeze score 79
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +7%
      Y/Y
      Gross margin 83%
      contracting
      EPS growth −120%
      Y/Y
      Free cash flow $43.3M
      Buyback $359.9M
      remaining
      Balance sheet $1.6B
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 54%
      annualized · 1-yr
      Max drawdown −40%
      past year
      ATR 4.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed May 6, 2026
      FY26 revenues · FY2026 Initiated $3.57B – $3.6B
      prior FY $3.44B midpoint +4.3% Y/Y
      FY26 non-GAAP EPS · FY2026 Non-GAAP Initiated $2.10 – $2.15

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +38% Bullish
      Price vs 50-day avg
      +12% Bullish
      RSI (14)
      60 Neutral
      MACD trend
      Negative Bearish
      52-week position
      93% Bullish
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $55 › 200d $45 — 50d above 200d
      Institutional flow Accumulating
      78 of 345 funds reported for Jun 30 · net +576.9K sh shares · +23 new
      Insider flow Distributing
      Net -$317.8K over 90 days · 100% sells
      Short interest Rising
      9.44% of float · ▲ +16.0% MoM · 7.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      345 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $28 Now $62 · 93% 52-wk high $65
      vs 200-day avg +38% vs 50-day avg +12%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      BRKR
      Bruker Corp
      this stock
      $9.37B +32.1% +7.3% 9.4%
      ABT
      Abbott Laboratories
      $179.51B -19.2% +5.7% 28.9 1.4%
      SYK
      Stryker Corp
      $126.60B -9.0% +11.2% 38.2 1.8%
      MDT
      Medtronic plc
      $106.51B -13.9% +8.4% 22.3 1.5%
      BSX
      Boston Scientific Corp
      $65.77B -54.3% +5.5% 18.5 1.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      363
      % held
      85.8%
      Reported
      78 of 345
      Top holder
      Orbis Allan Gray Ltd
      Held Float
      View
      Held by Funds
      Fund positions
      349
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      14.6M
      Days to cover
      7.2d
      Change
      +2.0M sh
      View
      Short Volume
      Short vol %
      75%
      As of
      Jul 24, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      77
      Value
      $4.2K
      As of
      Jun 24, 2026
      View
      Off-Exchange
      Off-exchange %
      53.2%
      Week of
      Jun 29, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$317.8K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Thomas R Carper
      Amount
      $1.0K–$15.0K
      Traded
      Apr 17, 2023
      View
      Financials
      Financials
      Revenue (FY)
      $3.4B
      Net income (FY)
      $-8.6M
      EPS diluted
      $-0.15
      View
      Buybacks
      Authorized
      $500.0M
      Remaining
      $359.9M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $120.5K
      Shares
      2.0K
      Filed
      Jul 15, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Aug 4, 2026
      Last call
      Jun 4, 2026
      View
      Investor Relations
      Latest news
      Bruker Announces Date and Time of…
      Published
      Jul 24, 2026
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      BRKR +4.9% +6.4% +40.7% +3.3% +32.1%
      SPY -1.7% +0.7% +6.4% -1.2% +8.3%
      vs SPY +6.6% +5.7% +34.4% +4.4% +23.9%

      Capital returns

      Latest dividend
      $0.05 / share · ex Jun 22, 2026
      Paid (TTM)
      $0.20 / share · 4 payouts
      Dividend yield (TTM, derived)
      0.32%
      Buyback program · as of May 31, 2025
      Authorized
      $500.00M
      Spent (derived)
      $140.10M
      Remaining
      $359.90M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1109354 CUSIP 116794108 13F (30d) 74 filings 74 filers Visit website Investor relations